Quanterix Corporation

NASDAQ:QTRX

Medical - Devices

Healthcare
$2.07 +15.80%

+$0.46 today

Market cap
$98.28M
Beta
1.12
P/E (TTM)
-1.5
EPS (TTM)
-$2.22
52W Low $2.40High $8.77

Volume 3.54M

Average 1.15M

QTRX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Quanterix CorporationNASDAQ: QTRX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $5.46M a year earlier. Trailing-twelve-month stock-based compensation was $9.79M. Over 3 fiscal years it compounded at +10.3% a year.

Context

  • Stock-based compensation amounted to 14.9% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.45M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$20.72M+3.7% YoY
LTMMar 2026
$9.79M+79.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+3.7%——
3-year CAGR+10.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
20.72M USD
Year-over-year change
+3.7%
4-year CAGR
+6.7%

Stock-Based Compensation vs competitors

How QTRX compares with its peers on the latest reported figures

  • QTRX's LTM Mar 2026 stock-based compensation of $9.79M is the 6th largest of the 11 companies compared; the peer median is $9.58M.
  • Its year-over-year change of +79.2% is the highest of 11, against a peer median of -22.3%.
  • Stock-based compensation amounts to 6.8% of revenue for QTRX, versus a peer median of 14.7%.
QTRX Competitors Peer median
Stock-Based Compensation for QTRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMOutset Medical, Inc.LTM Mar 2026$16.09M -33.3%-16.9%13.7%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M -30.6%+0.2%14.7%
CVRXCVRx, Inc.LTM Mar 2026$11.51M +11.1%+41.7%19.5%
SENSSenseonics Holdings, Inc.LTM Mar 2026$10.59M +14.3%+5.6%26.0%
MASS908 Devices Inc.LTM Mar 2026$9.88M -14.0%+11.0%17.1%
QTRXQuanterix CorporationLTM Mar 2026$9.79M +79.2%+10.3%6.8%
VMDViemed Healthcare, Inc.LTM Mar 2026$9.27M +29.4%+20.6%3.2%
INGNInogen, Inc.LTM Mar 2026$7.82M +9.7%-13.3%2.2%
NNOXNano-X Imaging Ltd.LTM Dec 2025$4.19M -42.3%-39.2%32.2%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$2.38M -344.3%—5.4%
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding QTRX) $9.58M-22.3%+2.9%14.7%

Competitors are the stored peer set for QTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.69M)(96.7M)(32.33M)(38.53M)(107.15M)
Depreciation & Amortization4.85M5.35M8.38M8.36M18.93M
Deferred Income Tax801K(226K)00(5.87M)
Stock-Based Compensation15.98M15.44M16.76M19.99M20.72M
Change in Working Capital(12.19M)2.07M(11.8M)(18.79M)(2.35M)
Accounts Receivables(6.85M)5.16M(6.7M)(7.7M)10.61M
Inventory(8.09M)5.39M(5.36M)(6.68M)4.03M
Accounts Payables2.41M(5.36M)1.19M723K(528K)
Other Working Capital343K(3.11M)(933K)(5.13M)(16.47M)
Other Non-Cash Items340K25.79M92K(6.19M)(1.51M)
Operating Cash Flow(47.91M)(48.27M)(18.9M)(35.16M)(77.24M)
Capital Expenditures(13.62M)(11.73M)(3.79M)(3.37M)(2.61M)
Acquisitions (Net)0000(93.23M)
Purchases of Investments00(175.61M)(295.61M)(69.76M)
Sales of Investments0031M216.71M215.83M
Other Investing Activities7.28M520K000
Investing Cash Flow(6.34M)(11.21M)(148.4M)(82.27M)50.23M
Debt Repayment(7.74M)0000
Common Stock Issued269.72M2.31M2.89M3.07M738K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.82M0(198K)(2.61M)(1.45M)
Financing Cash Flow270.8M2.31M2.69M456K(708K)
Effect of Forex Changes(92K)(538K)301K(734K)1.57M
Net Change in Cash216.46M(57.71M)(164.31M)(117.71M)(26.14M)
Free Cash Flow(61.52M)(60M)(22.69M)(38.53M)(79.85M)

Quanterix Corporation

NASDAQ:QTRX

Intrinsic Alpha fair value

Locked

Current Price

$2.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.